{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:36:21Z","timestamp":1790217381975,"version":"4.1.0"},"reference-count":31,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"\n BACKGROUND AND OBJECTIVE:<\/jats:title>\n Bevacizumab intravitreal injection, a vascular endothelial growth factor inhibitor, is used to treat retinopathy of prematurity (ROP). However, concerns have been raised regarding its systemic absorption and effect on developing tissues including brain. This study compared neurodevelopment at 18 months\u2019 corrected age in preterm infants of &lt;29 weeks\u2019 gestation treated with bevacizumab versus laser ablation.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n Data from the Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network databases were retrospectively reviewed. Infants born at &lt;29 weeks\u2019 in 2010\u20132011 with treated ROP were studied. Neurodevelopmental outcome at 18 months was assessed by using neurologic examination and the Bayley Scales of Infant and Toddler Development Third Edition. Regression analyses were performed.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n Of 125 treated infants, 27 received bevacizumab and 98 laser. The bevacizumab group, compared with laser, obtained a median Bayley Scales of Infant and Toddler Development Third Edition motor composite score of 81 (interquartile range, 70\u201391) versus 88 (79\u201397), a language composite score of 79 (65\u201397) versus 89 (74\u201397), and a cognitive score of 90 (80\u2013100) versus 90 (85\u2013100). Difference was detected on the motor score only (P = .02). Odds of severe neurodevelopmental disabilities (Bayley scores &lt;70, severe cerebral palsy, hearing aids, or bilateral blindness) was 3.1 times higher (95% confidence interval: 1.2\u20138.4) in infants treated with bevacizumab versus laser after adjusting for gestational age, gender, maternal education, Score for Neonatal Acute Physiology-II score, bronchopulmonary dysplasia, sepsis, and severe brain injury.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n Preterm infants treated with bevacizumab versus laser had higher odds of severe neurodevelopmental disabilities. Further investigation on the long-term safety of antivascular endothelial growth factor treatment of ROP is needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2015-3218","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T08:28:50Z","timestamp":1458203330000},"source":"Crossref","is-referenced-by-count":262,"title":["Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity"],"prefix":"10.1542","volume":"137","author":[{"given":"Julie","family":"Morin","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Ophthalmology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy Mai","family":"Luu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Ophthalmology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Superstein","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Ophthalmology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis H.","family":"Ospina","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Ophthalmology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Ophthalmology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Simard","sequence":"additional","affiliation":[{"name":"School of Rehabilitation, University of Montreal, Montreal, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhuti","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Mount Sinai Hospital, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakesh S.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Mount Sinai Hospital, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond N.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Mount Sinai Hospital, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,4,1]]},"reference":[{"key":"2021120921372205600_B1","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/01.iae.0000244293.94251.20","article-title":"Laser treatment for retinopathy of prematurity: evolution in treatment technique over 15 years.","volume":"26","author":"Hurley","year":"2006","journal-title":"Retina"},{"issue":"1","key":"2021120921372205600_B2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/pan.12310","article-title":"Beyond survival; influences of blood pressure, cerebral perfusion and anesthesia on neurodevelopment.","volume":"24","author":"McCann","year":"2014","journal-title":"Paediatr Anaesth"},{"issue":"11","key":"2021120921372205600_B3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"2021120921372205600_B4","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3928\/0191-3913-20070301-10","article-title":"Effect of diode laser retinal ablative therapy for threshold retinopathy of prematurity on the visual field: results of goldmann perimetry at a mean age of 11 years.","volume":"44","author":"McLoone","year":"2007","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"2","key":"2021120921372205600_B5","first-page":"228","article-title":"Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options.","volume":"6","author":"Mutlu","year":"2013","journal-title":"Int J Ophthalmol"},{"issue":"9902","key":"2021120921372205600_B6","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity.","volume":"382","author":"Hellstr\u00f6m","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"2021120921372205600_B7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.earlhumdev.2011.05.009","article-title":"Mediators involved in retinopathy of prematurity and emerging therapeutic targets.","volume":"87","author":"Mataftsi","year":"2011","journal-title":"Early Hum Dev"},{"issue":"7","key":"2021120921372205600_B8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"2021120921372205600_B9","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity.","volume":"98","author":"Darlow","year":"2013","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"1","key":"2021120921372205600_B10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","article-title":"Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity.","volume":"14","author":"Law","year":"2010","journal-title":"J AAPOS"},{"key":"2021120921372205600_B11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12886-015-0001-7","article-title":"Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.","volume":"15","author":"Menke","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"2021120921372205600_B12","doi-asserted-by":"crossref","DOI":"10.5005\/jp\/books\/10305_12","article-title":"From neonatal neurology: some clues for interpreting fetal findings","volume-title":"Fetal Neurology","author":"Amiel-Tison","year":"2009"},{"issue":"8","key":"2021120921372205600_B13","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaophthalmol.2013.400","article-title":"Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.","volume":"131","author":"Karaca","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"2021120921372205600_B14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.","volume":"153","author":"Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2021120921372205600_B15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.","volume":"33","author":"Mart\u00ednez-Castellanos","year":"2013","journal-title":"Retina"},{"key":"2021120921372205600_B16","unstructured":"The Canadian Neonatal Network\n . CNN publications. Available at: www.canadianneonatalnetwork.org\/portal\/CNNHome\/Publications.aspx. Accessed August 13, 2015"},{"issue":"5","key":"2021120921372205600_B17","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-3233","article-title":"Interinstitutional variation in prediction of death by SNAP-II and SNAPPE-II among extremely preterm infants.","volume":"124","author":"Dammann","year":"2009","journal-title":"Pediatrics"},{"key":"2021120921372205600_B18","volume-title":"Bayley Scales of Infant and Toddler Development","author":"Bayley","year":"2005","edition":"3rd ed"},{"issue":"4","key":"2021120921372205600_B19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1469-8749.1997.tb07414.x","article-title":"Development and reliability of a system to classify gross motor function in children with cerebral palsy.","volume":"39","author":"Palisano","year":"1997","journal-title":"Dev Med Child Neurol"},{"issue":"10","key":"2021120921372205600_B20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/pch\/15.10.667","article-title":"Retinopathy of prematurity: recommendations for screening.","volume":"15","author":"Jefferies","year":"2010","journal-title":"Paediatr Child Health"},{"key":"2021120921372205600_B21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/OPTH.S11650","article-title":"Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity.","volume":"4","author":"Velez-Montoya","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"2021120921372205600_B22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1167\/iovs.12-11291","article-title":"Hyperoxia causes regression of vitreous neovascularization by downregulating VEGF\/VEGFR2 pathway.","volume":"54","author":"Liu","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"2021120921372205600_B23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/org.6.2.11687","article-title":"VEGF in the nervous system.","volume":"6","author":"Rosenstein","year":"2010","journal-title":"Organogenesis"},{"issue":"2","key":"2021120921372205600_B24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.","volume":"56","author":"Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"2021120921372205600_B25","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","article-title":"Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection.","volume":"35","author":"Hong","year":"2015","journal-title":"Retina"},{"issue":"1","key":"2021120921372205600_B26","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.","volume":"90","author":"Carneiro","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"2021120921372205600_B27","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/bjophthalmol-2012-302451","article-title":"Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.","volume":"97","author":"Zehetner","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"2021120921372205600_B28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1542\/peds.2005-0249","article-title":"Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia.","volume":"116","author":"Ehrenkranz","year":"2005","journal-title":"Pediatrics"},{"issue":"5","key":"2021120921372205600_B29","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1542\/peds.106.5.998","article-title":"Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years.","volume":"106","author":"Msall","year":"2000","journal-title":"Pediatrics"},{"issue":"1","key":"2021120921372205600_B30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity.","volume":"53","author":"Salman","year":"2015","journal-title":"Ophthalmic Res"},{"issue":"2","key":"2021120921372205600_B31","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/IAE.0000000000000301","article-title":"Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.","volume":"35","author":"Chen","year":"2015","journal-title":"Retina"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3218\/1093953\/peds_20153218.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-3218\/1093953\/peds_20153218.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:15:45Z","timestamp":1639098945000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/137\/4\/e20153218\/81499\/Neurodevelopmental-Outcomes-Following-Bevacizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,1]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,4,1]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-3218","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,1]]},"article-number":"e20153218"}}